Related Experiment Video
Updated: Feb 16, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity
Jian Xu1, Yue Du1, Wen-Juan Liu1,2
1a Institute of Medicinal Biotechnology , Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing , China.
Abstract:
Fibrosarcomas are highly aggressive malignant tumors. It is urgently needed to explore targeted drugs and modalities for more effective therapy. Matrix metalloproteinases (MMPs) play important roles in tumor progression and metastasis, while several MMPs are highly expressed in fibrosarcomas. In addition, tissue inhibitor of metalloproteinase 2 (TIMP2) displays specific interaction with MMPs. Therefore, TIMP2 may play an active role in the development of fibrosarcoma-targeting agents. In the current study, a TIMP2-based recombinant protein LT and its enediyne-integrated analog LTE were prepared; furthermore, the fibrosarcoma-binding intensity and antitumor activity were investigated. As shown, intense and selective binding capability of the protein LT to human fibrosarcoma specimens was confirmed by tissue microarray. Moreover, LTE, the enediyne-integrated analog of LT, exerted highly potent cytotoxicity to fibrosarcoma HT1080 cells, induced apoptosis, and caused G2/M arrest. LTE at 0.1 nM markedly suppressed the migration and invasion of HT1080 cells. LTE at tolerated dose of 0.6 mg/kg inhibited the tumor growth of fibrosarcoma xenograft in athymic mice. The study provides evidence that the TIMP2-based reconstituted analog LTE may be useful as a targeted drug for fibrosarcome therapy.
Insights
A novel tissue inhibitor of metalloproteinase 2 (TIMP2)-based protein, LTE, shows selective binding to fibrosarcoma. This targeted drug effectively inhibits fibrosarcoma growth, migration, and invasion, offering a promising new therapy.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Fibrosarcomas are aggressive tumors requiring novel therapeutic strategies.
- Matrix metalloproteinases (MMPs) are implicated in fibrosarcoma progression and metastasis.
- Tissue inhibitor of metalloproteinase 2 (TIMP2) interacts with MMPs, suggesting its potential in targeted therapy.
Purpose of the Study:
- To develop and evaluate a TIMP2-based recombinant protein (LT) and its analog (LTE) for fibrosarcoma targeting.
- To assess the binding affinity, cytotoxicity, and antitumor efficacy of LTE against fibrosarcoma.
Main Methods:
- Preparation of TIMP2-based recombinant protein LT and enediyne-integrated analog LTE.
- Tissue microarray analysis to confirm fibrosarcoma-binding intensity of LT.
- In vitro cytotoxicity assays, apoptosis induction, cell cycle analysis, and migration/invasion assays using HT1080 cells treated with LTE.
- In vivo efficacy study of LTE in a fibrosarcoma xenograft mouse model.
Main Results:
- Protein LT demonstrated intense and selective binding to human fibrosarcoma specimens.
- LTE exhibited potent cytotoxicity, induced apoptosis, and caused G2/M cell cycle arrest in HT1080 fibrosarcoma cells.
- LTE significantly suppressed HT1080 cell migration and invasion at nanomolar concentrations.
- LTE inhibited fibrosarcoma xenograft tumor growth in mice at a tolerated dose.
Conclusions:
- The TIMP2-based analog LTE shows significant potential as a targeted therapeutic agent for fibrosarcoma.
- LTE's ability to selectively target fibrosarcoma and inhibit tumor growth warrants further investigation for clinical application.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020